University of California San Francisco

Neil Mehta, MD

Mehta
Neil
Mehta
MD

Associate Professor of Medicine

General Hepatology and Liver Transplantation

Department of Medicine

Address

400 Parnassus Avenue, #A740
San Francisco, CA 94143
United States

    Biography

    Dr. Neil Mehta is a gastroenterologist and specialist in liver transplantation.

    In his research, Mehta examines liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include outcomes for patients who undergo liver transplantation and cardiac iron overload in patients with chronic liver disease. He frequently lectures in the community and at the university on these subjects.

    At the UCSF School of Medicine, Mehta supervises the training of residents as well as fellows in both gastroenterology and liver transplant medicine. He also delivers lectures on liver disease to UCSF medical students studying metabolism and nutrition.

    Mehta earned his medical degree at UCSF and completed a residency in internal medicine at the University of Pennsylvania. He completed fellowships in gastroenterology and liver transplantation at UCSF.

    Education

    Institution Degree Dept or School End Date
    University of California, San Francisco M.D. Medicine 2006

    Board Certifications

    American Board of Internal Medicine
    American Board of Internal Medicine - Gastroenterology
    American Board of Internal Medicine - Transplant Hepatology

    Collaboration Interests

    I am interested in:

    • policy change

    Clinical Expertise

    Alcoholic Liver Disease

    Autoimmune Hepatitis

    Cirrhosis

    Drug-Induced Hepatitis

    Fulminant Hepatic Failure

    Hemochromatosis

    Hepatitis B

    Hepatitis C

    Hepatocellular Carcinoma (Liver Cancer)

    Liver Transplantation

    Living Donor Liver Transplantation

    Nonalcoholic Fatty Liver Disease

    Polycystic Liver Disease

    Primary Biliary Cirrhosis

    Primary Sclerosing Cholangitis

    Clinical Trials

    1. Related Conditions: Liver Cancer, Cirrhosis, Hepatitis B, Cancer, General, Hepatocellular Cancer| Start Date: | End Date:

    Program Affiliations

    UCSF Liver Center

    In the News

    December, 16, 2020 | UCSF General Surgery Residency Program

    Research Narrative

    Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

    • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
    • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

    Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

    Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

    Research Interests

    Hepatocellular carcinoma (HCC)

    Liver transplantation outcomes including expanded criteria liver transplants

    Cardiopulmonary complications of chronic liver disease

    Liver injury and repair (Liver transplantation)

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 230
    1. Social and clinical determinants of liver transplant evaluation in hepatocellular carcinoma: A multicenter cohort study.
      Tincopa M, Bridi L, Vodkin I, Yilma M, Zhou K, Kwong A, Singh J, Mehta N, Kuo A, Hirose R, Wisel SA, Steggerda JA, Freise C, Ajmera V| | PubMed
    2. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.
      Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG| | PubMed
    3. Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.
      Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle M, Macarulla T, Yopp A, Vogel A, Ohtsuka M, Ebata T, El-Meteini M, Abdelghafar MF, O'Kane G, El-Gendi A, Meyer T, Hong SK, Bhangui P, Finn R, Chan ACY, Mazzaferro V, Kim DS, Zhou J, Dong J, Hibi T, Wu H, Sapisochin G, Chieh Kow AW| | PubMed
    4. The Ascendancy of Yttrium-90 Radioembolization: Contemporary National Trends Among Liver Transplant Candidates With Hepatocellular Carcinoma.
      Salem R, Kwong AJ, Kim E, Kulik L, Mehta N| | PubMed
    5. Impact of hepatitis C viremia on overall survival and hepatic decompensation among patients with unresectable HCC receiving immunotherapy.
      Lee EY, Tang W, Price JC, Kelley RK, Gordan JD, Lai JC, Fong L, Mehta N, Li M| | PubMed
    6. BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma.
      Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer J, Parikh ND, Pillai A, Salem R, Sapisochin G, Tabrizian P, Yopp A, Yarchoan M, HCC-Live Steering Committee| | PubMed
    7. Liver transplant center prioritization of patients with low-dropout-risk hepatocellular carcinoma is associated with worse waitlist outcomes for remaining candidates.
      Amara D, Melehy A, Smullin C, Ebaid S, Kaldas FM, Farmer D, Stock P, Bui AA, Mehta N, Agopian V| | PubMed
    8. PEPCAL: A Heuristic Framework for Teaching Generative AI to Continuing Professional Education Providers and Faculty Developers.
      MacNeill H, Masters K, Benjamin J, Mehta N, Agrawal A, Valanci-Aroesty S| | PubMed
    9. Changes in Life Expectancy After Stroke Among Americans Aged 50 and Above by Sex, 1996-2018.
      Bramajo O, Chakraborty M, Lisabeth L, Mehta N| | PubMed
    10. Twelve tips for teaching research skills in the age of agentic AI: A guide for health professions educators.
      Mehta N, Benjamin J, Mehta S, Valanci S, MacNeill H, Masters K| | PubMed
    11. The 3C model: a simple prompt engineering framework for generative artificial intelligence.
      Damania R, Hrdy M, Mehta N, Wolbrink T| | PubMed
    12. High mortality at safety-net hospitals for patients with cirrhosis.
      Shah S, Yilma M, Omer S, Shui A, Kim NJ, Zhou K, Tana M, Mehta N| | PubMed
    13. Cost-Effectiveness Analysis of Resection, Ablation and Radiation Segmentectomy for Solitary Hepatocellular Carcinoma ≤3 cm from a U.S. Payor's Perspective.
      Wu X, Vakil P, Sarwar A, Faiz Z, Heller M, Lehrman E, Fidelman N, Mehta N, Lokken RP| | PubMed
    14. A call for clarity: a unified checklist for reporting use of large language models in writing scientific manuscripts.
      Mehta N, Felder RM, Kodish E, Imrey PB, Frankel RM| | PubMed
    15. Using locally-hosted Small Language Models (SLMs) to protect student, patient and research subject data in Health Professions Education.
      Masters K, Valanci-Aroesty S, Benjamin J, Mehta N, MacNeill H| | PubMed
    16. Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multisite Conjoint Analysis.
      Kao KD, Troost JP, Yang JD, Salgia R, Woolen SA, Mehta N, Hoteit MA, Jalal PK, El Dahan KS, Daher D, Quirk L, Patel N, Nayak A, Gamez J, Alsudaney M, Hernandez P, Bhongade M, Singal AG, Parikh ND| | PubMed
    17. Economic Burden of Recurrence in Early-Stage Hepatocellular Carcinoma Treated with Surgical Resection or Local Ablation in the United States: A Retrospective Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
      Mehta N, Wang L, Kamble S, Song Y, Gao E, Siegel A, Lax A, Sundaresan S, Zhang A, Wei V, Malhotra U| | PubMed
    18. Social drivers of differences in hepatocellular carcinoma (HCC) stage of diagnosis, treatment, and survival in a large, integrated health care system.
      Yilma M, Houhong Xu R, Tucker LS, Saxena V, Voelkel J, Muzzin M, Lee J, Mehta N, Mukhtar N| | PubMed
    19. Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma.
      Kim NG, Yao FY, Kwong AJ, Mehta N| | PubMed
    20. Patients who underwent TIPS face increases in hernia incarceration rates compared to patients managed with paracentesis: An analysis of prevalence and risk factors.
      Vissa A, Far AT, Lai JC, Mehta NJ, Kolli KP, Ge J| | PubMed
    21. Not Replaced, but Reinvented: AI Education Pathways to Prepare Future Physicians to Lead Healthcare Transformation.
      Mehta N, Mehta S, Rubenstein A, Wood SK| | PubMed
    22. From Confusion to Clarity: Generative AI as a Public Health Ally in the Age of Misinformation.
      Mehta S, Mehta N| | PubMed
    23. Outcomes from Referral to Transplant for Patients with MASLD: A California Liver Network Study.
      Lim TY, Steggerda JA, Trivedi H, Luu M, Vipani A, Adjei MA, Singh J, Zhou K, Kwong A, Tincopa M, Vodkin I, Ajmera V, Mehta N, Freise CE, Yilma M, Hirose R, Kuo A, Wisel SA| | PubMed
    24. Too High, Just Right, or Not Enough? Rethinking Alpha-Fetoprotein Thresholds for Hepatocellular Carcinoma Screening.
      Mehta N, Parikh ND| | PubMed
    25. Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma.
      Núñez K, Sandow T, Burton J, Hibino M, Gimenez J, Cohen A, Mehta N, Thevenot P| | PubMed
    26. Back to the Future: Long-Term Leadership Lessons From the COVID-19 Pandemic.
      Frankel R, Brogley Webb J, Bowen J, Mehta N, Isaacson JH| | PubMed
    27. Addressing educational overload with generative AI through dual coding and cognitive load theories.
      Mehta N, Benjamin J, Agrawal A, Valanci S, Masters K, MacNeill H| | PubMed
    28. Center Variation and Disparities in Expedited Evaluation for Liver Transplant Candidates - A Multicenter Competing Risk Analysis.
      M. Yilma, H. Braun, K. Zhou, A. Kwong, J. Singh, S. Wisel, M. Tincopa, C. Freise, N. Mehta, R. Hirose| | UCSF Research Profile
    29. Development of a Dynamic Model for Urgency of Liver Transplantation in Hepatocellular Carcinoma.
      T. Pan, A. Kwong, N. Mehta, W. Kim, L. Tian, V. Charu| | UCSF Research Profile
    30. Disparities in Referral for Liver Transplant Evaluation in Individuals with Hepatocellular Carcinoma: The California Liver Network.
      M.A. Tincopa, L. Bridi, I. Vodkin, M. Yilma, K. Zhou, A. Kwong, J. Singh, N. Mehta, A. Kuo, R. Hirose, S. Wisel, H. Trivedi, J. Steggerda, C. Freise, V. Ajmera| | UCSF Research Profile
    31. Fewer Liver Transplant Recipients with HCC Are Waiting =6 Months for Transplant in the United States.
      A. Kwong, J. Norman, V. Charu, T. Ghaziani, N. Mehta| | UCSF Research Profile
    32. Impact of Normothermic Machine Perfusion on Access to Liver Transplantation in Patients With Primary Hepatic Malignancies.
      Amara D, Melehy A, Ebaid S, Kaldas FM, Farmer DG, Stock P, Bui AAT, Mehta N, Agopian VG| | PubMed
    33. Outcomes from Referral to Transplant for Patients with MASLD: A California Liver Network Study.
      S.A. Wisel, J.A. Steggerda, H. Trivedi, A. Vipani, T. Lim, M. Adjei, J. Singh, K. Zhou, A. Kwong, M. Tincopa, I. Vodkin, V. Ajmera, N. Mehta, C.E. Freise, M. Yilma, R. Hirose, A. Kuo| | UCSF Research Profile
    34. Supporting Struggling Learners in the Clinical Setting.
      Isaacson JH, Christensen T, Nielsen C, Zack A, Mehta N| | PubMed
    35. Should Transplant Criteria Be Broadened Beyond United Network for Organ Sharing (UNOS) Downstaging Protocol to Include Larger Tumors?.
      Allison J. Kwong, Neil Mehta| | UCSF Research Profile
    36. Machine learning improves post-transplantation HCC recurrence prediction.
      Li PJ, Ashraf Ganjouei A, Syed S, Mehta N, Alseidi A, Adam MA| | PubMed
    37. Validation of the Toronto recurrence inference using machine-learning for post-transplant hepatocellular carcinoma model.
      Li Z, Chen IC, Centonze L, Magyar CTJ, Choi WJ, Ivanics T, O'Kane GM, Vogel A, Erdman L, De Carlis L, Lerut J, Lai Q, Agopian VG, Mehta N, Chen CL, Sapisochin G| | PubMed
    38. Assessment of Large Language Model Performance on Medical School Essay-Style Concept Appraisal Questions: Exploratory Study.
      Mehta S, Haddad EN, Burke IB, Majors AK, Maeda R, Burke SM, Deshpande A, Nowacki AS, Lindenmeyer CC, Mehta N| | PubMed
    39. Cutting into Change: Reflection on Surgeon Diet and Professional Identity.
      Rajan T, Mehta N| | PubMed
    40. Social determinants of health are associated with liver transplant evaluation and listing in a safety-net referral cohort.
      Bangaru S, Wang MC, Sumethasorn M, Wang S, Wong C, Omer S, Kim N, Shah S, Yilma M, Tana M, Mehta N, Benhammou JN, Zhou K| | PubMed
    41. The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma.
      Joshua S. Norman, Neil Mehta| | UCSF Research Profile
    42. Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.
      Singal AG, Yang JD, Jalal PK, Salgia R, Mehta N, Hoteit MA, Kao K, Daher D, El Dahan KS, Hernandez P, Nayak A, Kim N, Pham S, Gamez J, Troost JP, Parikh ND| | PubMed
    43. A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction.
      Li PJ, Tabrizian P, Daher D, Gaviria F, Ajmera V, Montalvan-Sanchez EE, Gutierrez JA, Zhou K, Delebecque F, Garcia N, Barrick B, Wong C, Nephew L, Holden J, Dave S, Schnickel GT, Rich NE, Florman SS, Sapisochin G, Yao F, Singal AG, Mehta N| | PubMed
    44. Reply: Downstaging of hepatocellular carcinoma before liver transplantation-More details, more significance.
      Xu E, Mehta N| | PubMed
    45. Longer travel and traffic are associated with adult liver transplant waitlist mortality in the United States.
      Zhou K, Albertian R, Wong C, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Cockburn MG| | PubMed
    46. Association Between Health Care Discrimination and Medical Mistrust Among Black Assigned Female at Birth Adults with Minoritized Sexual and Gender Identities in the United States.
      Noh M, Mehta N, Kim C, Bond K, Threats M, Jackson JW, Nnawulezi N, Agénor M| | PubMed
    47. DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
      Singal AG, Reddy KR, Colombo M, Morris HL, Mospan AR, Cabrera R, Kelley RK, Kilpatrick RD, Trevisani F, Farinati F, Giannini EG, Mehta N, Fried MW, Sangro B, DAA-PASS and ITA.LI.CA Investigators| | PubMed
    48. Differential aging trends among candidates for liver transplant with and without HCC.
      Jutras G, Mehta N, Lai JC| | PubMed
    49. Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.
      Xu E, Tabrizian P, Gutierrez J, Hoteit M, Ghaziani T, Zhou K, Parikh N, Ajmera V, Aby E, Shui A, Marino R, Martin A, Wong C, Kao K, Dave S, Florman S, Yao F, Mehta N| | PubMed
    50. Weight-Based Health Care Discrimination and Cervical Cancer Screening Among Black Sexual and Gender Minoritized Assigned Female at Birth Adults in the United States.
      Singh S, Mehta N, Noh M, Bond K, Threats M, Jackson JW, Nnawulezi N, Mercedes M, Agénor M| | PubMed
    51. Twelve tips on applying AI tools in HPE scholarship using Boyer's model.
      Benjamin J, Masters K, Agrawal A, MacNeill H, Mehta N| | PubMed
    52. Creating custom GPTs for faculty development: An example using the Johari Window and Crucial Conversation frameworks for providing feedback to struggling students.
      Mehta N, Nielsen C, Zack A, Christensen T, Isaacson JH| | PubMed
    53. The California Liver Network: Foreign Born Patients and their progression through liver transplant evaluation.
      Mignote Yilma, Kali Zhou, Allison Kwong, Steven Wisel, Monica Tincopa, Jasleen Singh, Justin Steggerda, Alexander Kuo, Veeral Ajmera, Hirsh Trivedi, Aarshi Vipani, Irine Vodkin, Hillary Braun, Neil Mehta, Chris Friese, Peter Stock, Ryutaro Hirose| | UCSF Research Profile
    54. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.
      Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, Singal AG, Yang JD| | PubMed
    55. Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
      Singal AG, Quirk L, Boike J, Chernyak V, Feng Z, Giamarqo G, Kanwal F, Ioannou GN, Manes S, Marrero JA, Mehta N, Pillai A, Shaheen NJ, Shaukat A, Sirlin CB, Verna E, Wani S, Wilson Woods A, Yang JD, Parikh ND| | PubMed
    56. Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers.
      Norman JS, Li PJ, Kotwani P, Yao FY, Pham S, Gamez J, Mehta N| | PubMed
    57. Reflections From the Pandemic: Is Connectivism the Panacea for Clinicians?
      Benjamin J, Pillow T, MacNeill H, Masters K, Agrawal A, Mehta N| | PubMed
    58. Economic Disadvantage During Childhood, Obesity, and Diabetes Across Three Birth Cohorts of Older Mexicans.
      Zazueta-Borboa JD, Samper-Ternent R, Wong R, Mehta N| | PubMed
    59. Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma.
      Zhou K, Nguyen L, Tabrizian P, Mehta N| | PubMed
    60. Yttrium-90 Radioembolization Has Become the Most Utilized Bridging Treatment for Liver Transplant Candidates in the United States.
      Salem R, Kwong AJ, Kim N, Sze DY, Mehta N| | PubMed
    61. Pedagogy and generative artificial intelligence: Applying the PICRAT model to Google NotebookLM.
      Mehta N, Agrawal A, Benjamin J, Mehta S, MacNeill H, Masters K| | PubMed
    62. Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.
      Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, Gruttadauria S, Iavarone M, Mazzarelli C, Simonotti N, Yao F, Mazzaferro V, Llovet JM| | PubMed
    63. Investigating feelings of imposterism in first-year medical student narratives.
      Kruskie ME, Frankel RM, Isaacson JH, Mehta N, Byram JN| | PubMed
    64. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.
      Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N| | PubMed
    65. Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System.
      Yilma M, Houhong Xu R, Saxena V, Muzzin M, Tucker LY, Lee J, Mehta N, Mukhtar N| | PubMed
    66. Recent Advances in Liver Transplantation for Hepatocellular Carcinoma.
      Li PJ, Shah S, Mehta N| | PubMed
    67. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma.
      Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG| | PubMed
    68. Embracing the illusion of explanatory depth: A strategic framework for using iterative prompting for integrating large language models in healthcare education.
      Mehta S, Mehta N| | PubMed
    69. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
      Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD| | PubMed
    70. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index.
      Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG| | PubMed
    71. Development and validation of a biomarker index for HCC treatment response.
      Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD| | PubMed
    72. Bridging the rural-urban gap in access to liver transplantation.
      Zhou K, Shah S, Thompson LK, Mehta N| | PubMed
    73. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation.
      Li M, Bhoori S, Mehta N, Mazzaferro V| | PubMed
    74. THU-470-YI Analysis of treatment benefits and prognostic factors for posttransplant hepatocellular carcinoma recurrence in a large Euro-American-Asian cohort.
      Zhihao Li, Itsuko Chih-Yi Chen, Grainne O'Kane, Arndt Vogel, Luciano De Carlis, Leonardo Centonze, Quirino Lai, Neil Mehta, Chao-Long Chen, Gonzalo Sapisochin| | UCSF Research Profile
    75. Role of biomarkers in the diagnosis and management of HCC.
      Al-Hasan M, Mehta N, Yang JD, Singal AG| | PubMed
    76. 163 A PRACTICAL POINTS-BASED MODEL TO PRIORITIZE LIVER TRANSPLANT CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE MODERN ERA.
      Joshua S. Norman, Neil Mehta, Vivek Charu, Jane Liang, Allison J. Kwong| | UCSF Research Profile
    77. Barriers to liver transplant referral in safety net settings: A national provider survey.
      Hundt M, Chen A, Donovan J, Kim N, Yilma M, Tana M, Mehta N, Zhou K| | PubMed
    78. EP74 COMPARATIVE ANALYSIS OF RESPONSE RATE AND TIME TO PROGRESSION AMONG NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTHCARE SYSTEM IN NORTHERN CALIFORNIA.
      Xiaoran Li, Steven Lam, Belia O. Roybal, Sreepriya Balasubramanian, Varun Saxena, Monica Muzzin, Richie Houhong Xu, Farhad Ferzanegan, Robert Freed, Neil Mehta, Mignote Yilma, Jeffrey K. Lee, Brock A. Macdonald, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar| | UCSF Research Profile
    79. Tu1568 COMPARATIVE ANALYSIS OF THE SAFETY OF NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTH CARE SYSTEM IN NORTHERN CALIFORNIA.
      Steven Lam, Xiaoran Li, Belia O. Roybal, Nizar A. Mukhtar, Sreepriya Balasubramanian, Varun Saxena, Monica Muzzin, Richie Houhong Xu, Farhad Ferzanegan, Robert Freed, Neil Mehta, Mignote Yilma, Jeffrey K. Lee, Brock A. Macdonald, Krisna P. Chai, Suk I. Seo| | UCSF Research Profile
    80. Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC).
      Mehta N| | PubMed
    81. Abstract No. 158 Cost-Effectiveness Analysis of Resection, Ablation, and Radiation Segmentectomy for Solitary Hepatocellular Carcinoma = 3 cm with Curative Intent.
      X. Wu, P. Vakil, M. Heller, E. Lehrman, N. Fidelman, N. Mehta, R. Lokken| | UCSF Research Profile
    82. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities.
      Martin SP, Mehta N, Emamaullee J| | PubMed
    83. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
      Norman JS, Mehta N| | PubMed
    84. Twelve tips on creating and using custom GPTs to enhance health professions education.
      Masters K, Benjamin J, Agrawal A, MacNeill H, Pillow MT, Mehta N| | PubMed
    85. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?"
      Norman JS, Mehta N| | PubMed
    86. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
      Hassan OT, Behr SC, Ohliger MA, Fowler KJ, Gill RM, Fidelman N, Mehta N, Choi HH| | PubMed
    87. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
      Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N| | PubMed
    88. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma.
      Yilma M, Mehta N| | PubMed
    89. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
      Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N| | PubMed
    90. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.
      Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ, North American Living Liver Donor Innovation Group (NALLDIG)| | PubMed
    91. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome.
      Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R| | PubMed
    92. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals.
      Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K| | PubMed
    93. Geographic disparities in access to liver transplantation.
      Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N| | PubMed
    94. 730 IMPACT OF SURVEILLANCE AND SOCIAL DETERMINANTS OF HEALTH ON TREATMENT RECEIPT AND HEALTHCARE COSTS IN PATIENTS WITH HCC.
      Amit G. Singal, Karl M. Kilgore, Elizabet Shvets, Neehar D. Parikh, Neil Mehta, Ahmet B. Ozbay, Christie Teigland, Omar Hafez, Amy L. Schroeder, Audrey Yang, Jill K. Schinkel| | UCSF Research Profile
    95. Tu1550 UTILITY OF A BIOMARKER-DERIVED SCORE FOR TREATMENT RESPONSE ASSESSMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.
      Jeff Liang, Po-Yi Li, Joshua S. Norman, Yee Hui Yeo, Hirsh D. Trivedi, Walid S. Ayoub, Alexander Kuo, Marc L. Friedman, Tsuyoshi Todo, Irene Kim, Georgios Voidonikolas, Todd Brennan, Steven Wisel, Kambiz Kosari, Rola Saouaf, Nicholas N. Nissen, Neil Mehta, Ju Dong Yang| | UCSF Research Profile
    96. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
      Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY| | PubMed
    97. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?
      Wu X, Lokken RP, Mehta N| | PubMed
    98. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection.
      Hoffman D, Shui A, Gill R, Syed S, Mehta N| | PubMed
    99. How does climate change impact our patients?
      Gordon IO, Mehta N, Isaacson JH, Khatri SB| | PubMed
    100. Abstract No. 251 ? FEATURED ABSTRACT Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for Downstaging of Hepatocellular Carcinoma Before Liver Transplant.
      X. Wu, A. Kwong, M. Heller, R. Lokken, N. Fidelman, N. Mehta| | UCSF Research Profile
    101. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.
      Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND| | PubMed
    102. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates.
      Wu X, Heller M, Kwong A, Fidelman N, Mehta N| | PubMed
    103. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation.
      Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM| | PubMed
    104. Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination.
      Patterson WM, Greene BD, Tefera L, Bena J, Milinovich A, Mehta N, Chung MK, Kapadia S, Svensson LG, Cameron SJ| | PubMed
    105. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
      Huang AC, Dodge JL, Yao FY, Mehta N| | PubMed
    106. Abstract No. 261 Cost-effectiveness analysis of interventional liver-directed therapies for a single, small (< 3 cm) hepatocellular carcinoma in liver transplant candidates.
      X. Wu, M. Heller, A. Kwong, N. Fidelman, N. Mehta| | UCSF Research Profile
    107. Impact and future of telemedicine amidst the COVID-19 pandemic: a systematic review of the state-of-the-art in Latin America.
      Nieblas B, Okoye K, Carrión B, Mehta N, Mehta S| | PubMed
    108. Nodular Regenerative Hyperplasia After Liver Transplant; It's All in the Presentation.
      Chen AK, Lunow-Luke T, Yamaguchi S, Praglin C, Agudelo E, Mehta N, Dirks R, Braun HJ, Gardner JM, Roberts JP, Syed SM, Roll GR| | PubMed
    109. 531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT.
      Varun Saxena, Liyan Liu, Joanna B. Ready, Mai Sedki, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar, Sreepriya Balasubramanian, Brock A. Macdonald, Neil Mehta, Julie A. Schmittdiel| | UCSF Research Profile
    110. EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA.
      Mignote Yilma, Jackson Voelkel, Richie Houhong Xu, Leu-Yen Tucker, Monica Muzzin, Varun Saxena, Neil Mehta, Jeffrey K. Lee, Suk I. Seo, Brock A. Macdonald, Joanna B. Ready, Sreepriya Balasubramanian, Nizar A. Mukhtar| | UCSF Research Profile
    111. National experience with living donor liver transplantation for hepatocellular carcinoma.
      Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N| | PubMed
    112. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
      Lee MMY, Docherty KF, Sattar N, Mehta N, Kalra A, Nowacki AS, Solomon SD, Vaduganathan M, Petrie MC, Jhund PS, McMurray JJV| | PubMed
    113. The impact of COVID-19 on professional identity.
      Byram JN, Frankel RM, Isaacson JH, Mehta N| | PubMed
    114. Climate Change and Medical Education: An Integrative Model.
      Sullivan JK, Lowe KE, Gordon IO, Colbert CY, Salas RN, Bernstein A, Utech J, Natowicz MR, Mehta N, Isaacson JH| | PubMed
    115. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
      Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N| | PubMed
    116. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis.
      Yilma M, Saxena V, Mehta N| | PubMed
    117. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
      Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB| | PubMed
    118. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
      Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N| | PubMed
    119. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation.
      Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC| | PubMed
    120. Migration is the driving force of rapid aging in Puerto Rico: A Research Brief.
      Matos-Moreno A, Santos-Lozada AR, Mehta N, de Leon CFM, Lê-Scherban F, De Lima Friche AA| | PubMed
    121. Racial Differences and In-Hospital Outcomes Among Hospitalized Patients with COVID-19.
      Elbadawi A, Elgendy IY, Joseph D, Eze-Nliam C, Rampersad P, Ouma G, Bhandari R, Kirksey L, Chaudhury P, Chung MK, Kalra A, Mehta N, Bartholomew JR, Sahai A, Svensson LG, Cameron SJ| | PubMed
    122. 433 THE ASSOCIATION OF SUSTAINED VIROLOGIC RESPONSE ON TREATMENT OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH HEPATITIS C.
      Neehar D. Parikh, Neil Mehta, Maarouf Hoteit, Ju Dong Yang, Binu V. John, Andrew M. Moon, Reena Salgia, Anjana A. Pillai, Ihab Kassab, Naba Saeed, Emil Thyssen, Piyush Nithani, Jeffrey Mckinney, Wesley Chan, Claire Durkin, Matthew Connor, Manaf Alsudaney, Brenda Durand, Nicholas N. Nissen, Hannah P. Kim, Raghavendra Paknikar, Nicole E. Rich, Matthew Schipper, Amit G. Singal| | UCSF Research Profile
    123. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis.
      Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N| | PubMed
    124. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.
      Deng LX, Mehta N| | PubMed
    125. Opioid use prior to liver transplant is associated with increased risk of death after transplant.
      Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL| | PubMed
    126. Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse.
      Varun Saxena, Neil Mehta| | UCSF Research Profile
    127. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions.
      Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C| | PubMed
    128. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.
      Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG| | PubMed
    129. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival.
      Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM| | PubMed
    130. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
      Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G| | PubMed
    131. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
      Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN| | PubMed
    132. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient.
      Zhou K, Mehta N| | PubMed
    133. OPIOID USE PRIOR TO LIVER TRANSPLANT IS ASSOCIATED WITH INCREASED RISK OF DEATH AFTER TRANSPLANT.
      Hillary Braun, Marisa P. Schwab, Chengshi Jin, Dominic Amara, Trevor Grace, Rhiannon Croci, Chris E. Freise, John P. Roberts, Neil Mehta, Ryutaro Hirose, Nancy L. Ascher| | UCSF Research Profile
    134. THU248 Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage.
      George Therapondos, Brian Lee, Gene Im, John Rice, Ann Lazar, Michael R. Lucey, Ethan Weinberg, Hyosun Han, Haripriya Maddur, R. Mark Ghobrial, Christine Hsu, Oren Fix, Sheila Eswaran, Kirti Shetty, Neha Jakhete, David Victor, David Foley, Neil Mehta, Mary Rinella, Thomas Schiano, Constance Mobley, Norah Terrault| | UCSF Research Profile
    135. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
      Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N| | PubMed
    136. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
      Lee E, Sarkar M, Dodge J, Kohi M, Mehta N| | PubMed
    137. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
      Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N| | PubMed
    138. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.
      Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C| | PubMed
    139. Correction to: Cardiologists' Perception of Wearable Device Data in Patients with Heart Failure.
      Mehta S, Mehta N, Tang WH, Young J| | PubMed
    140. Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management.
      Broome DT, Hilton CB, Mehta N| | PubMed
    141. Excess body weight, cigarette smoking, and type II diabetes incidence in the national FINRISK studies.
      Mehta N, Stenholm S, Männistö S, Jousilahti P, Elo I| | PubMed
    142. Cardiologists' Perception of Wearable Device Data in Patients with Heart Failure.
      Mehta S, Mehta N, Tang WH, Young J| | PubMed
    143. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.
      Cullaro G, Rubin JB, Mehta N, Lai JC| | PubMed
    144. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
      Mehta N, Dodge JL, Grab JD, Yao FY| | PubMed
    145. REPLY.
      Mehta N, Dodge JL, Yao FY| | PubMed
    146. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
      Gutin L, Yao F, Dodge JL, Grab J, Mehta N| | PubMed
    147. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study.
      Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J| | PubMed
    148. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
      Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC| | PubMed
    149. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.
      Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG| | PubMed
    150. Using an Adaptive, Self-Directed Web-Based Learning Module to Enhance Residents' Medical Knowledge Prior to a New Clinical Rotation.
      Brateanu A, Strang TM, Garber A, Mani S, Spencer A, Spevak B, Thomascik J, Mehta N, Colbert CY| | PubMed
    151. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
      Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F| | PubMed
    152. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
      Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
    153. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis.
      Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault| | UCSF Research Profile
    154. Systemic Treatment for Advanced Hepatocellular Carcinoma.
      Bouattour M, Mehta N, He AR, Cohen EI, Nault JC| | PubMed
    155. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning.
      Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J| | PubMed
    156. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?
      Mehta N, Yao FY| | PubMed
    157. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
      Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
    158. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria.
      Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N| | PubMed
    159. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
      Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM| | PubMed
    160. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
      Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND| | PubMed
    161. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead.
      Mehta N, Monto A, Yao FY| | PubMed
    162. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.
      Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G| | PubMed
    163. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
      Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
    164. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma.
      Samoylova ML, Mehta N, Roberts JP, Yao FY| | PubMed
    165. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence.
      Roberts DE, Kakar S, Mehta N, Gill RM| | PubMed
    166. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes.
      Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N| | PubMed
    167. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
      Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA| | PubMed
    168. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
      Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
    169. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis.
      Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA| | PubMed
    170. Re: "Social Media and the 21st-Century Scholar: How You Can Harness Social Media to Amplify Your Career".
      Chan TM, Stukus D, Leppink J, Duque L, Bigham BL, Mehta N, Thoma B| | PubMed
    171. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection.
      E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta| | UCSF Research Profile
    172. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?.
      M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta| | UCSF Research Profile
    173. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.
      Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G| | PubMed
    174. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis.
      B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault| | UCSF Research Profile
    175. Machine learning, natural language programming, and electronic health records: The next step in the artificial intelligence journey?
      Mehta N, Devarakonda MV| | PubMed
    176. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?
      Mehta N, Yao FY| | PubMed
    177. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels.
      Azeem N, Ajmera V, Hameed B, Mehta N| | PubMed
    178. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin.
      Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J| | PubMed
    179. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
      Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
    180. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
      Mehta N, Yao FY| | PubMed
    181. International Differences in the Risk of Death from Smoking and Obesity: The Case of the United States and Finland.
      Mehta N, Elo I, Stenholm S, Aromaa A, Heliövaara M, Koskinen S| | PubMed
    182. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
      Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY| | PubMed
    183. Social Media and the 21st-Century Scholar: How You Can Harness Social Media to Amplify Your Career.
      Chan TM, Stukus D, Leppink J, Duque L, Bigham BL, Mehta N, Thoma B| | PubMed
    184. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
      Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
    185. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
      Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY| | PubMed
    186. Resident-Led Handoffs Training for Interns: Online Versus Live Instruction with Subsequent Skills Assessment.
      Hill E, Cartabuke RH, Mehta N, Colbert C, Nowacki AS, Calabrese C, Mehdi A, Garber A, Mohmand M, Sinokrot O, Pile J| | PubMed
    187. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
      Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D| | PubMed
    188. Acute liver injury in a Glatopa-treated patient with MS.
      Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC| | PubMed
    189. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
      Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC| | PubMed
    190. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
      Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY| | PubMed
    191. Staying afloat in a sea of information: Point-of-care resources.
      Andrews R, Mehta N, Maypole J, Martin SA| | PubMed
    192. The Contribution of Weight Status to Black-White Differences in Mortality.
      Elo IT, Mehta N, Preston S| | PubMed
    193. Screening for hepatocellular carcinoma: What is missing?
      Mehta NJ, Celik AD, Peters MG| | PubMed
    194. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)?
      Mehta N, Yao FY| | PubMed
    195. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
      Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium| | PubMed
    196. Reply.
      Mehta N, Yao FY| | PubMed
    197. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
      Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N| | PubMed
    198. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
      Mehta N, Roberts JP, Yao FY| | PubMed
    199. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis.
      Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV| | PubMed
    200. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival.
      G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant| | UCSF Research Profile
    201. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan.
      Mehta N, Yao FY| | PubMed
    202. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study.
      G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix| | UCSF Research Profile
    203. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition?
      Mehta N, Yao FY| | PubMed
    204. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
      Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY| | PubMed
    205. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
      Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY| | PubMed
    206. Abstract 19009: The Association Between Clinical and Echocardiographic Imaging Findings and T2* in End Stage Liver Disease.
      Gabriel Brooks, Kathryn Brown, Neil Mehta, Karen Ordovas, Nevah Rubin, Elyse Foster, Atif Qasim| | UCSF Research Profile
    207. Online social support networks.
      Mehta N, Atreja A| | PubMed
    208. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
      Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP| | PubMed
    209. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
      Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP| | PubMed
    210. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.
      Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N| | PubMed
    211. Response to letter to the editors.
      Yao FY, Hameed B, Mehta N, Roberts JP| | PubMed
    212. The times they are a-changin': academia, social media and the JGIM Twitter Journal Club.
      Mehta N, Flickinger T| | PubMed
    213. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
      Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY| | PubMed
    214. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?.
      M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts| | UCSF Research Profile
    215. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
      Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
    216. BMJ endgames: a new web-based BMJ/JGIM collaboration.
      Srinivasan M, Mehta N| | PubMed
    217. EHRs in a web 2.0 world: time to embrace a problem-list Wiki.
      Mehta N, Vakharia N, Wright A| | PubMed
    218. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
      Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY| | PubMed
    219. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation.
      Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J| | PubMed
    220. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.
      Mehta N, Yao FY| | PubMed
    221. Reply: To PMID 23333661.
      Yao F, Mehta N| | PubMed
    222. Immunosuppression: Conventions and controversies.
      Mehta N, Hirose R| | PubMed
    223. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.
      Mehta N, Fidelman N, Sarkar M, Yao FY| | PubMed
    224. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization.
      Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff| | UCSF Research Profile
    225. Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy.
      Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD| | PubMed
    226. Usefulness and preference for tablet personal computers by medical students: are the features worth the money?
      Wiese D, Atreja A, Mehta N| | PubMed
    227. Development and psychometric validation of a brief instrument to measure satisfaction with online training.
      Avital M, Atreja A, Mehta N, Jain A| | PubMed
    228. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
      Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR| | PubMed
    229. Intensity-modulated radiation therapy in gynecologic malignancies.
      Salama JK, Roeske JC, Mehta N, Mundt AJ| | PubMed
    230. Physician - nurse practitioner teams in chronic disease management: the impact on costs, clinical effectiveness, and patients' perception of care.
      Litaker D, Mion L, Planavsky L, Kippes C, Mehta N, Frolkis J| | PubMed